Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 16 Brain Neoplasms 8 Glioma 4 Glioblastoma 4 Neoplasms 3 Uterine Cervical Neoplasms 2 Urogenital Diseases 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Prostate Adenocarcinoma 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1 Lymphoma, Follicular 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Lobular 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 361 Trastuzumab 352 Paclitaxel 304 Docetaxel 272 Letrozole 221 Capecitabine 221 Carboplatin 185 Doxorubicin 181 Tamoxifen 157 Radiotherapy 154 Epirubicin 145 Fulvestrant 143 Anastrozole 139 Surveys and Questionnaires 132 Exercise 128 pertuzumab 113 Vinorelbine 110 Blood Specimen Collection 109 exemestane 106 palbociclib 104 Bevacizumab 104 pembrolizumab 98 Magnetic Resonance Spectroscopy 97 Albumin-Bound Paclitaxel 87 Gemcitabine 84 Drug Therapy 83 Lapatinib 78 130-nm albumin-bound paclitaxel 72 Neoadjuvant Therapy 71 Cisplatin 69

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasms × fluciclovine F-18 × Clear all

NCT03036943 2018-12-19

FRONTIER

University of Oxford

Phase NA Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡